NCT01602822 - Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions

HIV

Interventions

DRUG

Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir

TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily

Trial Locations (1)

02215

Fenway Health, Boston